Kura Oncology (NASDAQ:KURA) Price Target Raised to $37.00

Kura Oncology (NASDAQ:KURA) had its price objective hoisted by HC Wainwright from $32.00 to $37.00 in a report issued on Thursday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Other analysts have also issued research reports about the company. Stifel Nicolaus lowered Kura Oncology from a “buy” rating to a “hold” rating and decreased their price objective for the company from $26.00 to $19.00 in a report on Monday, October 14th. Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. UBS Group initiated coverage on Kura Oncology in a report on Thursday, October 24th. They issued a “buy” rating and a $27.00 price target for the company. Wedbush restated an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a report on Monday, November 4th. Finally, StockNews.com lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.38.

Kura Oncology Trading Up 7.4 %

NASDAQ KURA opened at $10.80 on Thursday. Kura Oncology has a 52 week low of $9.06 and a 52 week high of $24.17. The company has a 50 day moving average price of $17.88 and a 200 day moving average price of $19.67. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm has a market cap of $839.81 million, a PE ratio of -4.58 and a beta of 0.86.

Institutional Investors Weigh In On Kura Oncology

Institutional investors and hedge funds have recently modified their holdings of the company. nVerses Capital LLC acquired a new stake in Kura Oncology during the 3rd quarter valued at approximately $25,000. ProShare Advisors LLC increased its stake in shares of Kura Oncology by 9.7% in the first quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock worth $384,000 after acquiring an additional 1,588 shares during the period. Aaron Wealth Advisors LLC raised its holdings in shares of Kura Oncology by 2.4% during the second quarter. Aaron Wealth Advisors LLC now owns 70,148 shares of the company’s stock worth $1,444,000 after purchasing an additional 1,673 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Kura Oncology by 5.4% during the second quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock valued at $793,000 after purchasing an additional 1,976 shares during the period. Finally, Hsbc Holdings PLC boosted its holdings in Kura Oncology by 13.4% in the second quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock valued at $374,000 after purchasing an additional 2,167 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.